<DOC>
	<DOCNO>NCT01164722</DOCNO>
	<brief_summary>RATIONALE : Infrared coagulator ablation may effective preventing development anal cancer patient anal neoplasia PURPOSE : This randomized phase III trial study infrared coagulator ablation see well work compare observation prevent anal cancer HIV-positive patient anal neoplasia .</brief_summary>
	<brief_title>Infrared Coagulator Ablation Observation Preventing Anal Cancer HIV-Positive Patients With Anal Neoplasia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate complete response rate 3 month 1 year HIV-seropositive patient high-grade anal intraepithelial neoplasia ( HGAIN ) treat infrared coagulator ( IRC ) ablation versus observation . Secondary - Determine tolerability safety IRC ablation versus observation patient . - Compare proportion patient HGAIN 1 year . - Evaluate response recurrence rate 1 year individual lesion patient treat regimen vs observation . - Determine incidence metachronous lesion patient . - Compare response recurrence rate 2 year individual lesion patient observation subsequently receive IRC ablation response recurrence rate 1 year patient initially treat IRC . OUTLINE : This multicenter study . Patients stratify accord site . Patients randomize 1 2 arm . - Arm I : Infrared coagulator ( IRC ) contact tip place direct contact lesion high-resolution anoscopy ( HRA ) guidance 1.5 second . IRC ablation reapplied level submucosal vessel reach . - One week IRC ablation , patient complete questionnaire regard pain , bleeding , complaint . - Arm II : Patients receive standard care undergo observation . After 12 month , patient may receive IRC ablation anal intraepithelial neoplasia lesion . NOTE : Patients may receive maximum 6 IRC treatment study ( 3 per year ) . Patients undergo physical exam , digital rectal exam , anal cytology , HRA baseline periodically study . After completion study therapy , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis highgrade anal intraepithelial neoplasia ( AIN ) meeting follow : AIN2 and/or AIN3 confirm biopsy ≥ 2 week ≤ 60 day enrollment 13 lesion lesion ≤ 15 mm diameter At least one highgrade AIN lesion still visible study entry HIVinfection document federally approve , license HIVtest conjunction screen test ( e.g. , ELISA , western blot , test ) HIVinfection , base prior ELISA western blot assay , record document another physician , allow provide patient undergoes approve antibody test confirm diagnosis Patients concurrent antiretroviral therapy history HIVpositivity base approve antibody test allow Detectable plasma HIV1 RNA also allow No perianal AIN , perianal condyloma , low vulvar intraepithelial neoplasia condyloma require treatment PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Life expectancy ≥ 2 year CD4 count ≥ 200/mm³ ANC &gt; 750/mm³ Platelet count ≥ 75,000/mm³ Hemoglobin ≥ 9.0 g/dL INR aPTT normal Negative pregnancy test Fertile patient must use effective contraception Female patient must undergo cervical pap smear ( cervix ) gynecologic evaluation within past 12 month Must capable complying requirement protocol Concurrent HPVrelated disease allow No history anal cancer No acute infection serious medical illness require treatment within past 14 day Fungal infection skin sexually transmit disease require treatment allow No concurrent malignancy require systemic therapy Kaposi sarcoma limit skin allow PRIOR CONCURRENT THERAPY : No prior infrared coagulator ( IRC ) ablation highgrade anal intraepithelial neoplasia ( HGAIN ) Prior HGAIN treat mean IRC within past 2 month allow At least 5 day since prior coumadin clopidogrel ≥ 7 day study therapy receive coumadin clopidogrel No concurrent anticoagulant therapy aspirin NSAIDs More 3 month since prior concurrent systemic corticosteroid , cytokine , immunomodulatory therapy ( e.g. , interferon ) local imiquimod No concurrent systemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>27 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>anal cancer</keyword>
	<keyword>HIV infection</keyword>
	<keyword>human papilloma virus infection</keyword>
	<keyword>neoplasm uncertain malignant potential</keyword>
	<keyword>high-grade squamous intraepithelial lesion</keyword>
</DOC>